-- China's drug regulator approved Changchun High-Tech Industry's (SHE:000661) clinical trial of its GenSci136 injection, according to a Friday filing with the Shenzhen bourse.
The injection is indicated for generalized myasthenia gravis, an acquired autoimmune condition characterized by impaired neuromuscular junction transmission, the filing said.
It affects muscle groups and impacts chewing, swallowing, raising arms, combing hair, and climbing stairs, among other actions.